BRIIEarnings•prnewswire•
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results
Sentiment:Neutral (40)
Summary
Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy Conference Calls...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 21, 2025 by prnewswire